It was previously reported that the rapalog Everolimus (RAD-001) in combination with ocreotide lanreotide (compared to placebo) improved the clinical picture of carcinoid patients by reducing circulating chromogranin A and 5-hydroxyindoleacetic acid, two tumor-secreted bioactive products responsible for some of the symptoms [36]. The gene discussed is CHGA; the disease is neoplasm.